Alzheimer's Association reports the 2026 LiBBY (Life's End Benefits of cannaBidiol and tetrahYdrocannabinol) trial tested a THC-plus-CBD oil for agitation at end of life. ClinicalTrials.Veeva lists 120 people with late-stage dementia and hospice eligibility, with spouses and partners only as study partners. That split shapes every safety question. Findings describe frail patients under hospice care, not partners who gave the oil or watched from home.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who was in the study?
- What did spouses and partners do?
- What improved and what harms appeared?
- What should spouses and partners do now?
Who was in the study?
ClinicalTrials.Veeva records the study group as adults 40 and older with major neurocognitive disorder, meaning advanced dementia, plus clinically significant agitation trial eligibility record. Hospice eligibility had to show through enrollment, FAST stage 6d, or ADEPT score 12 or higher.
FAST and ADEPT are scales that mark very late decline. This was a small, 12-week group of dying patients, not a broad dementia sample. Safety counts from this group do not transfer to healthier people.
- Age 40 or older with advanced dementia and ongoing agitation
- Hospice enrollment, or FAST 6d or ADEPT 12+ to prove end-stage illness
- Home care with regular visits to track behavior and drug use
What did spouses and partners do?
Every patient needed a study partner with about 5 or more hours of weekly contact. ClinicalTrials.Veeva notes that partner oversaw each dose at home and reported agitation and behavior changes at home visits.
Spouses, partners, and professional caregivers acted only as informants and hands-on givers under hospice and palliative teams. Georgetown University Medical Center states they were not dosed, and healthy volunteers and people with early or mild memory concerns were not enrolled Georgetown study description.
What improved and what harms appeared?
Neuroscience News describes the active oil as 2 mg THC plus 100 mg CBD taken twice daily. Dosing ran 12 weeks, starting at half dose in week 1, against placebo, with an optional 12-week open extension. Neuroscience News reports a 6.27-point greater drop at week 2 growing to 8.23 at week 12, with clinician-rated improvement in 87.2% versus 23.6% Neuroscience News summary.
Gains appeared early and grew through week 12. The Educated Patient notes overall adverse events were close between groups. Serious events including infections and deaths were higher with treatment at 23.3% versus 11.9%, though The Educated Patient notes investigators judged none drug-related The Educated Patient report.
What should spouses and partners do now?
Pennington Biomedical Research Center flags the key limit as generalizability: small, 12-week, topline-only results in dying patients with no regulatory approval. Those results do not establish safety for a spouse's own use or for early-stage agitation. Use the hospice team as the decision point.
Home use outside that supervision was not tested. Store any prescribed oil where only the assigned giver can reach it. Bring the bottle and behavior notes to each hospice visit.
- Bring agitation concerns to the hospice or palliative team first
- Do not borrow or share the trial oil for personal use or early memory concerns
- Keep a short daily note on agitation, sleep, falls, and other drugs for visits
You Might Also Like
- LiBBY Trial Findings for Late-Stage Dementia Agitation in 2026: Who Was Studied and Who Was Not for Spouses and Partners
- p-tau217 Findings a Decade Before Alzheimer’s Symptoms in 2026: Who Was Studied and Who Was Not for Spouses and Partners
- The NIA 2026 Dementia Care and Caregiving Summit Report: Service Gaps That Matter to Working Dementia Caregivers
